Anifrolumab, an Anti-Interferon-α Receptor Monoclonal Antibody, in Moderate-to-Severe Systemic Lupus Erythematosus - Wikidata - awgldk - TriplyDB

Anifrolumab, an Anti-Interferon-α Receptor Monoclonal Antibody, in Moderate-to-Severe Systemic Lupus Erythematosus

Anifrolumab, an Anti-Interferon-α Receptor Monoclonal Antibody, in Moderate-to-Severe Systemic Lupus Erythematosus

http://www.wikidata.org/entity/Q37633408

about

Modelling clinical systemic lupus erythematosus: similarities, differences and success stories Recent advances in the understanding of renal inflammation and fibrosis in lupus nephritis.Subcutaneous and intravenous belimumab in the treatment of systemic lupus erythematosus: a review of data on subcutaneous and intravenous administration.Simulating clinical trial visits yields patient insights into study design and recruitment.Lupus nephritis and B-cell targeting therapy.Antiphospholipid syndrome: an update for clinicians and scientists.Microglia-dependent synapse loss in type I interferon-mediated lupus.Biotherapy in Inflammatory Diseases of the CNS: Current Knowledge and Applications.Therapeutic options for cutaneous lupus erythematosus: recent advances and future prospects.Unmet Needs in the Pathogenesis and Treatment of Systemic Lupus Erythematosus.Novel Treatments in Lupus.IRF3 and type I interferons fuel a fatal response to myocardial infarction.Identification of biomarkers of response to abatacept in patients with SLE using deconvolution of whole blood transcriptomic data from a phase IIb clinical trial.Cytokine and autoantibody clusters interaction in systemic lupus erythematosus.Enhanced Inflammasome Activity in Systemic Lupus Erythematosus Is Mediated via Type I Interferon-Induced Up-Regulation of Interferon Regulatory Factor 1.Potential role of type I interferon in the pathogenic process leading to type 1 diabetes.Current and future therapies for SLE: obstacles and recommendations for the development of novel treatments.Increased Abundance of Plasmacytoid Dendritic Cells and Interferon-Alpha Induces Plasma Cell Differentiation in Patients of IgA Nephropathy.NF-κB inducing kinase is a therapeutic target for systemic lupus erythematosus.Type I IFN signature in childhood-onset systemic lupus erythematosus: a conspiracy of DNA- and RNA-sensing receptors?New Treatments for Systemic Lupus Erythematosus on the Horizon: Targeting Plasmacytoid Dendritic Cells to Inhibit Cytokine Production.Longitudinal association of type 1 interferon-induced chemokines with disease activity in systemic lupus erythematosus.Systemic lupus erythematosus and ocular involvement: an overview.Diagnostic and prognostic tests in systemic lupus erythematosus.Cell Death, Nucleic acids and Immunity: Inflammation beyond the Grave.Lupus Low Disease Activity State (LLDAS) attainment discriminates responders in a systemic lupus erythematosus trial: post-hoc analysis of the Phase IIb MUSE trial of anifrolumab.Recent developments in systemic lupus erythematosus pathogenesis and applications for therapy.Antibodies to watch in 2018.Lupus community panel proposals for optimising clinical trials: 2018.Increased RNA Editing May Provide a Source for Autoantigens in Systemic Lupus Erythematosus.Editorial: Interferon-Targeted Therapy for Systemic Lupus Erythematosus: Are the Trials on Target?Disease severity and prophylactic measures in patients with cutaneous lupus erythematosus: results of a worldwide questionnaire-based study.Advances in Biomarker-Guided Therapy for Pediatric- and Adult-Onset Neuroinflammatory Disorders: Targeting Chemokines/Cytokines.Characterisation of anifrolumab, a fully human anti-interferon receptor antagonist antibody for the treatment of systemic lupus erythematosus.Safety, tolerability and pharmacokinetics of subcutaneous and intravenous anifrolumab in healthy volunteers.Report of the inaugural Interferon Research Summit: interferon in inflammatory diseases.Interferons in Traumatic Brain and Spinal Cord Injury: Current Evidence for Translational Application.Human and Murine Evidence for Mechanisms Driving Autoimmune Photosensitivity SERPINB3 Delays Glomerulonephritis and Attenuates the Lupus-Like Disease in Lupus Murine Models by Inducing a More Tolerogenic Immune Phenotype The Dual Nature of Type I and Type II Interferons

P2860

Q28074217-6D613734-09B6-47EA-967C-C944D5747332 Q33806541-6B47D20A-47FF-4751-9142-50AD0822BA14 Q38605480-54905FA5-D342-4346-9195-47794F6D9837 Q38621372-7D9FC58D-527C-4267-BC2D-FE4084A2C24E Q38643755-0D0DA8BF-B68A-4CCD-A27B-A56F2EA93284 Q38679842-703B0FB0-DB24-4011-929B-C8669BEED9EA Q38725841-32EF673B-A3A4-47A1-8188-EA621C04B700 Q38729214-7F871374-4FFE-4ECD-A85E-A01036E508E2 Q38850089-738A5DB5-7E75-43A5-975D-7824E3173BFC Q39150632-AD7EB9F5-C379-4515-B06B-404C05CFE634 Q39164953-CE42D320-B356-4F88-99EF-5B11A8452912 Q46039774-86A25104-970D-4686-8375-DAC260D847FA Q47108999-C7C30FE0-2B36-4F5C-88B9-6544E3B1A031 Q47120444-42022EA8-60AC-4CAA-AC40-7B32C3EF2BE8 Q47359687-22D04703-AE1D-4664-8BA7-22415E5085EE Q47548945-0520DEE0-9E5D-45D9-8945-D6EEA954FEAB Q47552016-ABF101AA-EF95-4272-B1F6-94DAB9F6A04A Q48102522-9306D5D5-FF04-496E-AC3B-4CD6CD58B6D6 Q48250996-E3367563-4145-41DD-88F8-39DAF4235198 Q49299269-9DA5A5C4-7D61-4874-830A-11E4EFFE6AB1 Q49499785-056EC475-3132-4BE0-B6CC-6D0826757798 Q49830970-61D502EF-7D2F-4E6A-B851-7CB5B746EA46 Q49833678-457FEBFA-A7E0-4403-B620-F625E4A3D00A Q49966463-ACEC0BB6-5299-4232-B9EB-CFA4C26588B7 Q50034731-441D0ECA-96F5-4460-BDEA-4D5D172F6523 Q50053733-B377826E-2629-47F4-9CA5-B38CF5251B5F Q50068095-E299FA07-8700-4FBB-8DE6-8E61C3907105 Q50120289-BAD5CB93-7034-42E8-887A-14E6932D4D5B Q52320880-4DA59338-0FC0-43E6-99F3-D7D158DE2A59 Q52607307-B72365F2-E2AD-4329-BE9D-EDC198951BFD Q53675008-4857EBFC-7897-4064-9BB6-C1AE71DE9E18 Q55007548-F5BCF9E3-F541-4D67-97CB-13762F879CCA Q55052878-FF597D3D-E2F3-4AD4-BD2B-DC2438D7A213 Q55100613-B0418445-423E-48CD-8EE8-EB0E1E67DBDB Q55334068-006DD3A0-CD36-41BF-93D9-70E8477C3C64 Q55383884-6C51A304-1CB5-4A7F-8D45-01CF545DCF92 Q55429416-3192D033-6962-48D7-BDD5-DE6568006467 Q58572607-A54A9EC9-6279-4E8C-924C-125E7ABD1EB4 Q58750515-9A373A41-F86A-42C4-AB2B-A2301E4857EB Q58750649-CEEBE348-28EC-4B68-9BFF-074D3860CE5E

P2860

Anifrolumab, an Anti-Interferon-α Receptor Monoclonal Antibody, in Moderate-to-Severe Systemic Lupus Erythematosus

http://www.wikidata.org/entity/Q37633408

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on February 2017

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Anifrolumab, an Anti-Interfero ...... e Systemic Lupus Erythematosus

@en

Anifrolumab, an Anti-Interfero ...... Systemic Lupus Erythematosus.

@nl

type

label

Anifrolumab, an Anti-Interfero ...... e Systemic Lupus Erythematosus

@en

Anifrolumab, an Anti-Interfero ...... Systemic Lupus Erythematosus.

@nl

prefLabel

Anifrolumab, an Anti-Interfero ...... e Systemic Lupus Erythematosus

@en

Anifrolumab, an Anti-Interfero ...... Systemic Lupus Erythematosus.

@nl

P1433

Q37633408-E05FA05A-555C-4D4D-8F53-C9A210BFE2C9

P1476

Q37633408-D9F50EA4-F09A-4A68-B632-A4850B19F186

P2093

Q37633408-30726684-B72A-4970-B5D1-58F3F4A2AD86

Q37633408-3314EAD4-4661-492B-907E-D5B87E5C62BE

Q37633408-6FCDAC9D-80BD-48FA-BB47-2DCB2B4DB6AC

Q37633408-763911F9-63CE-43AE-AB0B-B0C2D7C6435E

Q37633408-931D8FAB-1861-432D-B67B-13AB7C497D9D

Q37633408-A9B61965-2BAB-4633-AD63-901207A52DBD

Q37633408-B1D85424-13CE-400D-8090-7BF161BB19FA

Q37633408-B4AA9BD7-B90F-4A52-8BEB-933911681D8E

Q37633408-D20FC320-7129-4638-90DA-6CB32B5E7276

Q37633408-DB27A2D3-77EF-45CB-B02E-B31C2D08898C

P2860

Q37633408-04D81DE5-A239-4AD4-A46F-3EDCB0E0BB6F

Q37633408-0A42E0A8-4AC2-4A2C-A721-17811AE9E2F4

Q37633408-0FDE8C52-21C5-4305-9466-07A5207E884C

Q37633408-13EE7975-09DB-4948-BB92-5613BA4F0032

Q37633408-2DC205BE-9608-462E-8DAB-937254D8B15A

Q37633408-3099F126-FD07-4EB2-99F8-63EB275918CC

Q37633408-31316D9A-F4DB-4E1B-9BA0-D4A42D1377AA

Q37633408-3267B56B-10F0-4B3A-B1C2-BD803084E28E

Q37633408-450DC7F6-E654-4DA2-B29B-2033011212E4

Q37633408-4535B623-EBF4-4C51-98FD-3AF5ED65F904

P304

Q37633408-4DC24693-8048-4DBB-A601-05B366B89FE0

P31

Q37633408-9FC8D112-66F8-4069-A52D-4EFF7089B7B7

P356

Q37633408-3698B2AC-F877-4D15-A2B0-E9B30EB03CFB

P433

Q37633408-5D4DBBF0-EC93-4F91-AA32-BBB0908F1F2D

P478

Q37633408-2E43192A-B7A7-4318-942C-08200D796BEC

P50

Q37633408-1398FE28-08D5-4C27-B4B4-F96FABA83B02

P577

Q37633408-6D6ECB5C-5165-4F0A-91AF-3F0D6E36A0E0

P698

Q37633408-E43B83A7-27BA-4F8F-AB63-2F293E152E17

P921

Q37633408-11C4CBB7-6468-4428-B24E-8DA552703F57

P932

Q37633408-9FC7BAA6-1BDA-43FC-BDB7-DE038444F10F

P356

P1433

Arthritis & Rheumatology

P1476

Anifrolumab, an Anti-Interfero ...... e Systemic Lupus Erythematosus

@en

P2093

CD1013 Study Investigators

http://www.w3.org/2001/XMLSchema#string

Gabor G Illei

http://www.w3.org/2001/XMLSchema#string

Joan T Merrill

http://www.w3.org/2001/XMLSchema#string

Jorn Drappa

http://www.w3.org/2001/XMLSchema#string

Kenneth Kalunian

http://www.w3.org/2001/XMLSchema#string

Liangwei Wang

http://www.w3.org/2001/XMLSchema#string

Philip Brohawn

http://www.w3.org/2001/XMLSchema#string

Richard Furie

http://www.w3.org/2001/XMLSchema#string

Stephen Yoo

http://www.w3.org/2001/XMLSchema#string

Victoria P Werth

http://www.w3.org/2001/XMLSchema#string

P2860

Regulation of type I interferon responses

Type I interferon blockade in systemic lupus erythematosus: where do we stand?

Emerging therapies for systemic lupus erythematosus--focus on targeting interferon-alpha

Efficacy and safety of epratuzumab in patients with moderate/severe active systemic lupus erythematosus: results from EMBLEM, a phase IIb, randomised, double-blind, placebo-controlled, multicentre study

The 1982 revised criteria for the classification of systemic lupus erythematosus

Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus

Type I interferon in the pathogenesis of lupus.

Numerical scoring for the BILAG-2004 index

A phase 2, randomised, placebo-controlled clinical trial of blisibimod, an inhibitor of B cell activating factor, in patients with moderate-to-severe systemic lupus erythematosus, the PEARL-SC study.

Long-term outcomes in lupus.

P304

376-386

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/ART.39962

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

69

http://www.w3.org/2001/XMLSchema#string

P50

Munther A. Khamashta

P577

2017-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28130918

http://www.w3.org/2001/XMLSchema#string

P921

P932

5299497

http://www.w3.org/2001/XMLSchema#string